Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

Erythropoietin (EPO) and LGD-4033 Interaction: Monitor | Peptide Database

Compound Profiles Erythropoietin (EPO) EPO | Red Blood Cell Stimulating Hormone EPO binds to erythropoietin receptors (EPOR) on erythroid progenitor cells in bone marrow, activating three interconnected signaling pathways: JAK2/STAT5, PI3K/AKT, and RAS/MAPK. T

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

Compound Profiles

Erythropoietin (EPO)

EPO | Red Blood Cell Stimulating Hormone

EPO binds to erythropoietin receptors (EPOR) on erythroid progenitor cells in bone marrow, activating three interconnected signaling pathways: JAK2/STAT5, PI3K/AKT, and RAS/MAPK. This promotes survival of red blood cell precursors by protecting them from apoptosis, accelerates proliferation and differentiation of erythroid cells, and increases hemoglobin production.

LGD-4033

Selective Androgen Receptor Modulator | Lean Mass

LGD-4033 binds to the androgen receptor with high affinity (Ki of approximately 1 nM), functioning as a potent and selective agonist in muscle and bone tissue. Like other SARMs, its tissue selectivity is mediated by differential cofactor recruitment: upon binding to the AR, LGD-4033 induces a receptor conformation that preferentially recruits coactivators expressed in skeletal muscle and bone, while showing minimal agonist activity in androgen-sensitive tissues such as the prostate and skin.

Combined Organ Load

Shared Safety Flags

Frequently Asked Questions

Can I take Erythropoietin (EPO) with LGD-4033?

Yes, but with caution. Both Erythropoietin (EPO) and LGD-4033 can raise blood pressure. Monitor BP regularly and consider adding cardiovascular support (cardarine, telmisartan, or similar). Regular monitoring is advised.

Is Erythropoietin (EPO) and LGD-4033 safe together?

Based on pharmacological analysis, this combination is considered monitor. However, shared safety flags include: blood pressure raising, carcinogenic risk. Monitor accordingly.

What are the interactions between Erythropoietin (EPO) and LGD-4033?

Both Erythropoietin (EPO) and LGD-4033 can raise blood pressure. Monitor BP regularly and consider adding cardiovascular support (cardarine, telmisartan, or similar). This assessment has 51% confidence and is inferred from pharmacological mechanism analysis.

How should I time Erythropoietin (EPO) and LGD-4033?

Erythropoietin (EPO) has a half-life of 4-12 hours (IV), ~25 hours (SubQ) and LGD-4033 has a half-life of ~24-36 hours. No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.

This interaction analysis is compiled from research literature and pharmacological mechanism data. This assessment is inferred from known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

comparison

What's the ideal 5/5 vs 10/3 ratio for Tesa/IPA and when to use each?

5/5 (equal parts) provides balanced GH stimulation suitable for general recovery. The 10/3 (higher tesamorelin) variant emphasizes visceral fat loss and metabolic effects. Choose 5/5 for at…

Source: peptide-db.com
comparison

What's the dose range for cognitive enhancement versus being too much?

The cognitive 'sweet spot' is 0.5-2 mg/kg body weight (roughly 35-140 mg for a 70 kg person). Doses above 2 mg/kg often shift from antioxidant to pro-oxidant effects, becoming counterproduc…

Source: peptide-db.com
comparison

What's the addiction risk of phenibut vs benzodiazepines?

Phenibut carries similar addiction and withdrawal risk to benzodiazepines despite not being a benzo. Physical dependence can develop in as little as 1-2 weeks of daily use, and withdrawal i…

Source: peptide-db.com
Research context

Read sources and limitations before applying a claim.

Community Research

Join others researching Cortagen — share findings, ask questions, and learn from real experiences Cortagen is a Khavinson bioregulator tetrapeptide (AEDP) with primary effects on the brain and central nervous system. Developed at Russia's St. Petersburg Institute of Bioregulation and Gerontology, it regulates inflammatory responses in the nervous system, restores balance between pro- and anti-oxidative processes, and stimulates interleukin-2 expression. Research shows potential benefits for ischemic brain injury recovery, nerve regeneration, and reducing autoimmune reactions affecting the CNS. Cortagen works through epigenetic regulation by penetrating cell nuclei and interacting with DNA to modulate gene expression. In the heart, it affects genes including Pass1, Hsc70, Bmp2, Wnt4, Eps15, and Eps15-rs. It powerfully regulates inflammatory responses in the nervous system, helping restore proper balance between oxidative and anti-oxidative processes. Cortagen stimulates IL-2 expression and helps regulate immune function, particularly by reducing autoimmune reactions.

Source: peptide-db.com ↗

Community Research

Join others researching Cyclic Glycine-Proline — share findings, ask questions, and learn from real experiences Endogenous cyclic dipeptide found in plasma, breast milk, and cerebrospinal fluid. Functions as metabolite of IGF-1, regulating its bioavailability through competitive binding to IGFBP-3. Demonstrates neuroprotective, cognitive-enhancing, and cardioprotective properties supported by clinical trials. Competes with IGF-1 for IGFBP-3 binding, normalizing bioavailable IGF-1 levels. Acts as positive allosteric modulator of AMPA and GABA-A receptors. Increases BDNF levels via Akt/MDM2-p53 pathway activation.

Source: peptide-db.com ↗
Practical and safety references

These excerpts are educational, not personalised medical instructions.

Dosage reference

Dosing Protocols

Sublingual administration is the most common route for 9-Me-BC in the nootropic community. The compound is typically supplied as a powder or in capsule form, with sublingual dosing preferred for improved bioavailability by bypassing first-pass hepatic metabolism. The powder is held under the tongue for 1-2 minutes before swallowing. Dosing should occur exclusively in the morning to minimize any risk of insomnia from dopaminergic stimulation, and strict sun avoidance must be maintained throughout the entire period of use. Standard Nootropic / Dopamine Restoration 5-15 mg Once daily in the morning Sublingual

Source: peptide-db.com ↗
Side effects

Common Side Effects

Gastrointestinal discomfort (diarrhea, abdominal pain) - mild and infrequent, reported at similar rates to placebo Upper respiratory tract infection (reported in clinical trials but not clearly drug-related) Fatigue and headache (uncommon, typically transient)

Source: peptide-db.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →

Continue learning

Related guides

03
Peptide Therapy Guide Editorial Team

HCG and HGH Interaction: Monitor | Peptide Database

Compound Profiles HCG Human Chorionic Gonadotropin | LH Receptor Agonist Binds to LH receptors on Leydig cells in testes, stimulating testosterone production with a half-life of 24-36 hours, peak levels 6-12 h…

Read guide →